#USA #VitaSmart #Bridge to Life #Duke University #Duke University, North Carolina

Introduction to the VitaSmart™ HOPE System

In a groundbreaking development for organ transplantation, Bridge to Life™ Ltd. has announced that Duke University Hospital is the first facility in the United States to utilize the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System after receiving FDA clearance. This innovative system aims to reshape how donor organs, particularly livers, are preserved and prepared for transplant, enhancing the potential for successful surgeries and better patient outcomes.

The Need for Advanced Preservation Techniques

The increasing demand for organ transplants has highlighted the challenges in preserving organs for optimal transplantation. Traditionally, organs have been stored in cold saline solutions, which limits their viability over time. The introduction of the VitaSmart™ system represents a major advancement in preserving livers, allowing for extended periods of viability before transplantation, particularly for organs obtained from Donation after Circulatory Death (DCD) donors.

Key Features of the VitaSmart™ HOPE System

The HOPE System operates by cooling donor livers to controlled, hypothermic temperatures while infusing them with oxygenated fluid. This method not only maximizes the organ's quality but also minimizes the risks associated with conventional preservation techniques.

Dr. Andrew Barbas, Associate Professor of Surgery at Duke University and the director of their liver transplant program, emphasized the importance of this innovative approach. He stated, “Hypothermic liver perfusion provides our team with yet another approach to expand the donor pool in liver transplantation.” This underlines the system's potential to make more organs available for transplantation, potentially saving more lives.

Clinical Trial Insights

The FDA's clearance is backed by impressive results from a multicenter, randomized clinical trial which focused on the efficacy of end-ischemic Hypothermic Oxygenated Perfusion (HOPE) compared to traditional static cold storage. Highlights from the trial included:

• - Early Trial Closure: The trial was concluded prematurely as an early analysis showed significant efficacy of the HOPE system.
• - Reduced Hospital Stay: Patients who received HOPE showed significantly shorter hospital stays, indicating improved recovery times and reduced healthcare costs.
• - Lower Incidence of Early Allograft Dysfunction: The use of the portal venous HOPE technique resulted in a reduced incidence of early complications related to liver transplants.

These findings present substantial implications for the future of liver transplantation, making the VitaSmart™ system a promising option for enhancing transplant outcomes.

Operational Benefits and Future Outlook

One of the pivotal advantages of the VitaSmart™ system is its flexibility in clinical application. The FDA clearance does not limit the duration of machine perfusion, allowing surgeons and clinicians to adapt their approach based on the specifics of each case. This flexibility can lead to better operational coordination, timing of transplants, and overall success rates.

Bridge to Life is also committed to robust supply chain management, maintaining a minimum of 60 days' worth of inventory to ensure uninterrupted access to their lifesaving solutions. This strategic approach not only mitigates risks but also empowers transplant centers to focus on what truly matters - patient care.

Conclusion: A New Era for Organ Transplantation

The introduction of the VitaSmart™ Hypothermic Oxygenated Perfusion System signifies a pivotal moment in organ transplantation science. With Duke University Hospital leading the charge as the first U.S. transplant center to deploy this innovative system, there is a renewed sense of optimism in the transplant community. The potential for improved patient outcomes and expanded donor organ accessibility presents a bright future for regions grappling with organ shortages.

Bridge to Life™ Ltd. continues to play a crucial role in advancing organ preservation technologies, setting the stage for a new era in healthcare aimed at saving lives through enhanced transplantation methods.